RolloverTreatment With Triumeq for People With ALS Following the Lighthouse II Trial
Status:
TERMINATED
Trial end date:
2025-06-03
Target enrollment:
Participant gender:
Summary
Triumeq is an approved medicine for HIV. The effectiveness of Triumeq in Amyotrophic Lateral Sclerosis (ALS) is being investigated in the Lighthouse II trial. This study aims to assess whether Triumeq is safe and effective at delaying ALS disease progression when given long term. It is available for participants who have completed the Lighthouse II study. The main measurements are safety, tolerability and survival.
The study will go for approximately 2 years.
Phase:
PHASE3
Details
Lead Sponsor:
Macquarie University, Australia
Treatments:
abacavir abacavir, dolutegravir, and lamivudine drug combination dolutegravir Lamivudine